MRI-defined T3, clear mesorectal fascia mid-low rectal cancer: is neoadjuvant treatment necessary?

Aim: Neoadjuvant treatments (nCRT) are becoming the standard treatment for patients with stage II or III mid-low rectal cancer. Recently, some studies have shown that surgery alone may be sufficient for patients with T3 rectal cancer. This raises the question of whether nCRT is necessary for all pat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Zeng, Ziwei (VerfasserIn) , Li, Ze (VerfasserIn) , Luo, Shuangling (VerfasserIn) , Huang, Liang (VerfasserIn) , Liang, Zhenxing (VerfasserIn) , Zheng, Xiaobin (VerfasserIn) , Li, Wenxin (VerfasserIn) , Xiong, Li (VerfasserIn) , Liu, Huashan (VerfasserIn) , Kang, Liang (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 15 January 2024
In: Journal of gastroenterology and hepatology
Year: 2024, Pages: 1-10
ISSN:1440-1746
DOI:10.1111/jgh.16451
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/jgh.16451
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.16451
Volltext
Verfasserangaben:Ziwei Zeng, Ze Li, Shuangling Luo, Liang Huang, Zhenxing Liang, Xiaobin Zheng, Wenxin Li, Li Xiong, Huashan Liu and Liang Kang

MARC

LEADER 00000caa a22000002c 4500
001 188143012X
003 DE-627
005 20240307020052.0
007 cr uuu---uuuuu
008 240222s2024 xx |||||o 00| ||eng c
024 7 |a 10.1111/jgh.16451  |2 doi 
035 |a (DE-627)188143012X 
035 |a (DE-599)KXP188143012X 
035 |a (OCoLC)1425200161 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Zeng, Ziwei  |d 1995-  |e VerfasserIn  |0 (DE-588)1286632560  |0 (DE-627)1843156342  |4 aut 
245 1 0 |a MRI-defined T3, clear mesorectal fascia mid-low rectal cancer  |b is neoadjuvant treatment necessary?  |c Ziwei Zeng, Ze Li, Shuangling Luo, Liang Huang, Zhenxing Liang, Xiaobin Zheng, Wenxin Li, Li Xiong, Huashan Liu and Liang Kang 
264 1 |c 15 January 2024 
300 |b Illustrationen 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 22.02.2024 
520 |a Aim: Neoadjuvant treatments (nCRT) are becoming the standard treatment for patients with stage II or III mid-low rectal cancer. Recently, some studies have shown that surgery alone may be sufficient for patients with T3 rectal cancer. This raises the question of whether nCRT is necessary for all patients with T3 rectal cancer. Therefore, this study compared the clinical outcomes of patients with MRI-defined T3, clear MRF mid-low rectal cancer treated with surgery alone (TME group) or nCRT followed by surgery (nCRT + TME group). Methods: A total of 1509 patients were enrolled in this study. After a 1:1 propensity score matching analysis, 480 patients were included in each group. The primary endpoint was 3-year disease-free survival (DFS). The secondary endpoints included the perioperative outcomes, histopathologic outcomes, and other follow-up outcomes. Results: nCRT had advantages in rates of sphincter-preserving surgery and tumor downstaging, but it was accompanied by a higher rate of enterostomies. At 3 years after surgery, local recurrence occurred in 3.3% of patients in the TME group and in 3.5% of patients in the nCRT + TME group (P = 0.914), the DFS rates were 78.3% in the TME group and 75.3% in the nCRT + TME group (P = 0.188), and the overall survival rates were 90.3% in the TME group and 89.9% in the nCRT + TME group (P = 0.776). Conclusions: Surgery alone versus nCRT followed by surgery may provide similar long-term oncological outcomes for patients with MRI-defined T3, clear MRF, and mid-low rectal cancer. nCRT may cause overtreatment in some patients. 
650 4 |a Local recurrence 
650 4 |a Magnetic resonance imaging 
650 4 |a Neoadjuvant treatment 
650 4 |a Rectal cancer 
650 4 |a Total mesorectal excision 
700 1 |a Li, Ze  |e VerfasserIn  |4 aut 
700 1 |a Luo, Shuangling  |e VerfasserIn  |4 aut 
700 1 |a Huang, Liang  |e VerfasserIn  |4 aut 
700 1 |a Liang, Zhenxing  |e VerfasserIn  |4 aut 
700 1 |a Zheng, Xiaobin  |e VerfasserIn  |4 aut 
700 1 |a Li, Wenxin  |e VerfasserIn  |4 aut 
700 1 |a Xiong, Li  |e VerfasserIn  |4 aut 
700 1 |a Liu, Huashan  |e VerfasserIn  |4 aut 
700 1 |a Kang, Liang  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of gastroenterology and hepatology  |d Oxford [u.a.] : Wiley-Blackwell, 1986  |g (2024) online ahead of print  |h Online-Ressource  |w (DE-627)320456951  |w (DE-600)2006782-3  |w (DE-576)091142849  |x 1440-1746  |7 nnas  |a MRI-defined T3, clear mesorectal fascia mid-low rectal cancer is neoadjuvant treatment necessary? 
773 1 8 |g year:2024  |g pages:1-10  |g extent:10  |a MRI-defined T3, clear mesorectal fascia mid-low rectal cancer is neoadjuvant treatment necessary? 
856 4 0 |u https://doi.org/10.1111/jgh.16451  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.16451  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20240222 
993 |a Article 
994 |a 2024 
998 |g 1286632560  |a Zeng, Ziwei  |m 1286632560:Zeng, Ziwei  |p 1  |x j 
999 |a KXP-PPN188143012X  |e 4490045921 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"recId":"188143012X","type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 22.02.2024"],"title":[{"title_sort":"MRI-defined T3, clear mesorectal fascia mid-low rectal cancer","subtitle":"is neoadjuvant treatment necessary?","title":"MRI-defined T3, clear mesorectal fascia mid-low rectal cancer"}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Zeng, Ziwei","given":"Ziwei","family":"Zeng"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Li, Ze","given":"Ze","family":"Li"},{"given":"Shuangling","family":"Luo","role":"aut","display":"Luo, Shuangling","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Huang, Liang","roleDisplay":"VerfasserIn","given":"Liang","family":"Huang"},{"family":"Liang","given":"Zhenxing","roleDisplay":"VerfasserIn","display":"Liang, Zhenxing","role":"aut"},{"family":"Zheng","given":"Xiaobin","roleDisplay":"VerfasserIn","display":"Zheng, Xiaobin","role":"aut"},{"role":"aut","display":"Li, Wenxin","roleDisplay":"VerfasserIn","given":"Wenxin","family":"Li"},{"given":"Li","family":"Xiong","role":"aut","display":"Xiong, Li","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Liu, Huashan","roleDisplay":"VerfasserIn","given":"Huashan","family":"Liu"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Kang, Liang","given":"Liang","family":"Kang"}],"relHost":[{"pubHistory":["1.1986 -"],"titleAlt":[{"title":"Gastroenterology and hepatology"}],"part":{"year":"2024","pages":"1-10","text":"(2024) online ahead of print","extent":"10"},"disp":"MRI-defined T3, clear mesorectal fascia mid-low rectal cancer is neoadjuvant treatment necessary?Journal of gastroenterology and hepatology","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"320456951","language":["eng"],"title":[{"subtitle":"official publication of the Asian Pacific Association for the Study of the Liver and the Asian Pacific Association of Gastroenterology","title":"Journal of gastroenterology and hepatology","title_sort":"Journal of gastroenterology and hepatology"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"1986","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell","dateIssuedDisp":"1986-","publisherPlace":"Oxford [u.a.] ; Oxford ; Oxford [u.a.]"}],"id":{"doi":["10.1111/(ISSN)1440-1746"],"eki":["320456951"],"zdb":["2006782-3"],"issn":["1440-1746"]}}],"physDesc":[{"extent":"10 S.","noteIll":"Illustrationen"}],"id":{"eki":["188143012X"],"doi":["10.1111/jgh.16451"]},"origin":[{"dateIssuedDisp":"15 January 2024","dateIssuedKey":"2024"}],"name":{"displayForm":["Ziwei Zeng, Ze Li, Shuangling Luo, Liang Huang, Zhenxing Liang, Xiaobin Zheng, Wenxin Li, Li Xiong, Huashan Liu and Liang Kang"]}} 
SRT |a ZENGZIWEILMRIDEFINED1520